

**PB 16 of 2020**

**National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 1)**

*National Health Act 1953*

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 89A(3) of the *National Health Act 1953*.

Dated 27 February 2020

**THEA DANIEL**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

1. **Name of Instrument**
2. This Instrument is the *National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2020 (No. 1)*.
3. This Instrument may also be cited as PB 16 of 2020.
4. **Commencement**

This Instrument commences on 1 March 2020.

1. **Amendment of *National Health (Continued Dispensing – Emergency Measures) Determination 2020.***

Schedule 1 amends the *National Health (Continued Dispensing – Emergency Measures) Determination 2020*.

Schedule 1 Amendments

1. Schedule 1, after entry for Cimetidine

*insert:*

|  |  |  |
| --- | --- | --- |
| Cinacalcet | Tablet 30 mg (as hydrochloride) | Oral |
|  | Tablet 60 mg (as hydrochloride) | Oral |
|  | Tablet 90 mg (as hydrochloride) | Oral |

1. Schedule 1, after entry for Glycine with carbohydrate

*insert:*

|  |  |  |
| --- | --- | --- |
| Glycomacropeptide and essential amino acid formula with vitamins, minerals, and low in tyrosine and phenylalanine | Sachets containing oral powder 35 g, 30 (TYR Sphere20) | Oral |

1. Schedule 1, after entry for Isotretinoin in the form Capsule 20 mg

*insert:*

|  |  |  |
| --- | --- | --- |
|  | Capsule 30 mg | Oral |

1. Schedule 1, after entry for Levodopa with carbidopa in the form Tablet (modified release) 200 mg-50 mg (as monohydrate)

*insert:*

|  |  |  |
| --- | --- | --- |
|  | Tablet (prolonged release) 200 mg-50 mg | Oral |

1. Schedule 1, entry for Levonorgestrel

*insert as first entry:*

|  |  |  |
| --- | --- | --- |
|  | Intrauterine drug delivery system 19.5 mg | Intrauterine |

1. Schedule 1, entry for Lisdexamfetamine

*insert as first entry:*

|  |  |  |
| --- | --- | --- |
|  | Capsule containing lisdexamfetamine dimesilate 20 mg | Oral |

1. Schedule 1, after entry for Lisdexamfetamine in the form Capsule containing lisdexamfetamine dimesilate 30 mg

*insert:*

|  |  |  |
| --- | --- | --- |
|  | Capsule containing lisdexamfetamine dimesilate 40 mg | Oral |

1. Schedule 1, after entry for Lisdexamfetamine in the form Capsule containing lisdexamfetamine dimesilate 50 mg

*insert:*

|  |  |  |
| --- | --- | --- |
|  | Capsule containing lisdexamfetamine dimesilate 60 mg | Oral |

1. Schedule 1, after entry for Tacrolimus in the form Capsule 2 mg

*insert:*

|  |  |  |
| --- | --- | --- |
|  | Capsule 3 mg (once daily prolonged release) | Oral |

1. Schedule 1, entry for Tiotropium

*insert as first entry:*

|  |  |  |
| --- | --- | --- |
|  | Capsule containing powder for oral inhalation 13 micrograms (as bromide) (for use in Zonda device) | Inhalation by Mouth |